<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03533244</url>
  </required_header>
  <id_info>
    <org_study_id>P2-86893-001</org_study_id>
    <nct_id>NCT03533244</nct_id>
  </id_info>
  <brief_title>A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia</brief_title>
  <acronym>SURPH</acronym>
  <official_title>A Multicenter, Prospective, Randomized, Double-Masked, Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of Topical AG-86893 in Patients With Pterygium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allgenesis Biotherapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allgenesis Biotherapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pterygium is a wing-shaped, benign tissue growth which forms on the surface of the&#xD;
      conjunctiva and grows towards the cornea. It can eventually lead to vision impairment. The&#xD;
      precise cause of pterygium formation is unknown but new blood vessel growth and fibroblastic&#xD;
      structures are characteristics of the disease. AG-86893 is an eye drop being developed to&#xD;
      treat hyperemia (redness) and growth of the pterygium.&#xD;
&#xD;
      Hypothesis&#xD;
&#xD;
        1. AG-86893 dosed three times daily for 28 consecutive days has an acceptable safety&#xD;
           profile as measured by the incidence and severity of adverse events (AEs) compared with&#xD;
           vehicle&#xD;
&#xD;
        2. At least 1 concentration of AG-86893 is effective, as measured by the mean change from&#xD;
           baseline in conjunctival hyperemia (redness), compared with vehicle&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 11, 2018</start_date>
  <completion_date type="Actual">October 25, 2019</completion_date>
  <primary_completion_date type="Actual">September 5, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Overall Conjunctival Hyperemia Score</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Assessed by digital ocular photography; each quadrant of the eye (superior, inferior, nasal, temporal) will be scored using a 5-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe) and graded by a reading center. The overall conjunctival score is the average of the four quadrants. Assessments are made by subtracting the score at Baseline from the score on Day 28. An increase in value indicates worsening of hyperemia, while a decrease indicates improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Conjunctival Hyperemia Score in the Quadrant With the Pterygium</measure>
    <time_frame>Baseline and Day 28</time_frame>
    <description>Assessed by digital ocular photography; the quadrant with the pterygium will be scored using a 5-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe) and graded by a reading center. Assessments are made by subtracting the score at Baseline from the score on Day 28. An increase in value indicates worsening of hyperemia, while a decrease indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Pterygium</condition>
  <arm_group>
    <arm_group_label>Vehicle Eye Drops</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One drop, three times daily to the study eye for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1% AG-86893 Eye Drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop, three times daily to the study eye for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.3% AG-86893 Eye Drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One drop, three times daily to the study eye for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.1% AG-86893 Eye Drops</intervention_name>
    <description>One drop, three times daily to the study eye for 28 days</description>
    <arm_group_label>0.1% AG-86893 Eye Drops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3% AG-86893 Eye Drops</intervention_name>
    <description>One drop, three times daily to the study eye for 28 days</description>
    <arm_group_label>0.3% AG-86893 Eye Drops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Eye Drops</intervention_name>
    <description>One drop, three times daily to the study eye for 28 days</description>
    <arm_group_label>Vehicle Eye Drops</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Good health with no clinically significant findings based on the medical history,&#xD;
             electrocardiogram, vital signs, blood chemistry, hematology, and urinalysis findings,&#xD;
             as determined by the investigator&#xD;
&#xD;
          -  Females of childbearing potential must have a negative pregnancy test at baseline and&#xD;
             must be on established, adequate contraception and males must use condoms if their&#xD;
             partner is of childbearing potential and their female partner should also use an&#xD;
             additional effective means of contraception, or they must agree to abstain from sexual&#xD;
             intercourse with a female partner for the duration of the study; contraception should&#xD;
             be continued for 3 months after the last dose.&#xD;
&#xD;
          -  Presence of pterygium with associated conjunctival hyperemia (redness) of grade â‰¥2 as&#xD;
             assessed by a central reading center.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of any ocular diseases other than pterygium or its sequelae&#xD;
             (after-effects), including neoplasia (uncontrolled overgrowth)&#xD;
&#xD;
          -  Diagnosis of ocular hypertension or glaucoma requiring use of intraocular&#xD;
             pressure-lowering medication&#xD;
&#xD;
          -  Use of contact lenses during the study in the study eye&#xD;
&#xD;
          -  History or evidence of ocular surgeries in the study eye at any time&#xD;
&#xD;
          -  History of liver dysfunction or current abnormal liver enzymes&#xD;
&#xD;
          -  Pregnancy, plans for pregnancy, or breastfeeding during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>M.T. Coroneo Pty Ltd</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H2Vision Centre</name>
      <address>
        <city>Sippy Downs</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bendigo Eye Clinic</name>
      <address>
        <city>Bendigo</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Essendon Eye Clinic</name>
      <address>
        <city>Essendon</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Geelong Eye Centre</name>
      <address>
        <city>Waurn Ponds</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lions Eye Institute</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 27, 2018</study_first_submitted>
  <study_first_submitted_qc>May 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2018</study_first_posted>
  <results_first_submitted>October 11, 2020</results_first_submitted>
  <results_first_submitted_qc>November 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 6, 2020</results_first_posted>
  <last_update_submitted>November 4, 2020</last_update_submitted>
  <last_update_submitted_qc>November 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pterygium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03533244/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT03533244/Prot_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vehicle Eye Drops</title>
          <description>One drop, three times daily to the study eye for 28 days&#xD;
Vehicle Eye Drops: One drop, three times daily to the study eye for 28 days</description>
        </group>
        <group group_id="P2">
          <title>0.1% AG-86893 Eye Drops</title>
          <description>One drop, three times daily to the study eye for 28 days&#xD;
0.1% AG-86893 Eye Drops: One drop, three times daily to the study eye for 28 days</description>
        </group>
        <group group_id="P3">
          <title>0.3% AG-86893 Eye Drops</title>
          <description>One drop, three times daily to the study eye for 28 days&#xD;
0.3% AG-86893 Eye Drops: One drop, three times daily to the study eye for 28 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vehicle Eye Drops</title>
          <description>One drop, three times daily to the study eye for 28 days&#xD;
Vehicle Eye Drops: One drop, three times daily to the study eye for 28 days</description>
        </group>
        <group group_id="B2">
          <title>0.1% AG-86893 Eye Drops</title>
          <description>One drop, three times daily to the study eye for 28 days&#xD;
0.1% AG-86893 Eye Drops: One drop, three times daily to the study eye for 28 days</description>
        </group>
        <group group_id="B3">
          <title>0.3% AG-86893 Eye Drops</title>
          <description>One drop, three times daily to the study eye for 28 days&#xD;
0.3% AG-86893 Eye Drops: One drop, three times daily to the study eye for 28 days</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.8" spread="12.4"/>
                    <measurement group_id="B2" value="54.7" spread="11.9"/>
                    <measurement group_id="B3" value="49.0" spread="10.7"/>
                    <measurement group_id="B4" value="51.2" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Overall Conjunctival Hyperemia Score</title>
        <description>Assessed by digital ocular photography; each quadrant of the eye (superior, inferior, nasal, temporal) will be scored using a 5-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe) and graded by a reading center. The overall conjunctival score is the average of the four quadrants. Assessments are made by subtracting the score at Baseline from the score on Day 28. An increase in value indicates worsening of hyperemia, while a decrease indicates improvement.</description>
        <time_frame>Baseline and Day 28</time_frame>
        <population>modified intent-to-treat (mITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Eye Drops</title>
            <description>One drop, three times daily to the study eye for 28 days&#xD;
Vehicle Eye Drops: One drop, three times daily to the study eye for 28 days</description>
          </group>
          <group group_id="O2">
            <title>0.1% AG-86893 Eye Drops</title>
            <description>One drop, three times daily to the study eye for 28 days&#xD;
0.1% AG-86893 Eye Drops: One drop, three times daily to the study eye for 28 days</description>
          </group>
          <group group_id="O3">
            <title>0.3% AG-86893 Eye Drops</title>
            <description>One drop, three times daily to the study eye for 28 days&#xD;
0.3% AG-86893 Eye Drops: One drop, three times daily to the study eye for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Overall Conjunctival Hyperemia Score</title>
          <description>Assessed by digital ocular photography; each quadrant of the eye (superior, inferior, nasal, temporal) will be scored using a 5-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe) and graded by a reading center. The overall conjunctival score is the average of the four quadrants. Assessments are made by subtracting the score at Baseline from the score on Day 28. An increase in value indicates worsening of hyperemia, while a decrease indicates improvement.</description>
          <population>modified intent-to-treat (mITT)</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.056" spread="0.120"/>
                    <measurement group_id="O2" value="-0.330" spread="0.109"/>
                    <measurement group_id="O3" value="-0.352" spread="0.109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>An empirical sample size estimation was used as this was an exploratory study. The null hypothesis is that there is no difference between AG-86893 and AG-86893 Vehicle. It is expected that the active group is at least 50% better than the vehicle.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.218</p_value>
            <p_value_desc>To reserve the family-wise error rate, the main treatment effect will be first assessed at the global level at alpha = 0.05. If this is significant, then pairwise comparisons will be conducted using the Bonferroni adjustment for multiplicity.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.290</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Conjunctival Hyperemia Score in the Quadrant With the Pterygium</title>
        <description>Assessed by digital ocular photography; the quadrant with the pterygium will be scored using a 5-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe) and graded by a reading center. Assessments are made by subtracting the score at Baseline from the score on Day 28. An increase in value indicates worsening of hyperemia, while a decrease indicates improvement.</description>
        <time_frame>Baseline and Day 28</time_frame>
        <population>Per protocol (PP)</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Eye Drops</title>
            <description>One drop, three times daily to the study eye for 28 days&#xD;
Vehicle Eye Drops: One drop, three times daily to the study eye for 28 days</description>
          </group>
          <group group_id="O2">
            <title>0.1% AG-86893 Eye Drops</title>
            <description>One drop, three times daily to the study eye for 28 days&#xD;
0.1% AG-86893 Eye Drops: One drop, three times daily to the study eye for 28 days</description>
          </group>
          <group group_id="O3">
            <title>0.3% AG-86893 Eye Drops</title>
            <description>One drop, three times daily to the study eye for 28 days&#xD;
0.3% AG-86893 Eye Drops: One drop, three times daily to the study eye for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Conjunctival Hyperemia Score in the Quadrant With the Pterygium</title>
          <description>Assessed by digital ocular photography; the quadrant with the pterygium will be scored using a 5-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe) and graded by a reading center. Assessments are made by subtracting the score at Baseline from the score on Day 28. An increase in value indicates worsening of hyperemia, while a decrease indicates improvement.</description>
          <population>Per protocol (PP)</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.111" spread="0.153"/>
                    <measurement group_id="O2" value="-0.429" spread="0.142"/>
                    <measurement group_id="O3" value="-0.500" spread="0.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.193</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.399</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Percent of Patients With a 1-point Decrease in Hyperemia Score in the Quadrant With the Pterygium</title>
        <description>Assessed by digital ocular photography; the quadrant with the pterygium will be scored using a 5-point scale and graded by a reading center. A 1-point reduction in hyperemia score is considered clinically meaningful.</description>
        <time_frame>Day 28</time_frame>
        <population>Per protocol (PP)</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle Eye Drops</title>
            <description>One drop, three times daily to the study eye for 28 days&#xD;
Vehicle Eye Drops: One drop, three times daily to the study eye for 28 days</description>
          </group>
          <group group_id="O2">
            <title>0.1% AG-86893 Eye Drops</title>
            <description>One drop, three times daily to the study eye for 28 days&#xD;
0.1% AG-86893 Eye Drops: One drop, three times daily to the study eye for 28 days</description>
          </group>
          <group group_id="O3">
            <title>0.3% AG-86893 Eye Drops</title>
            <description>One drop, three times daily to the study eye for 28 days&#xD;
0.3% AG-86893 Eye Drops: One drop, three times daily to the study eye for 28 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With a 1-point Decrease in Hyperemia Score in the Quadrant With the Pterygium</title>
          <description>Assessed by digital ocular photography; the quadrant with the pterygium will be scored using a 5-point scale and graded by a reading center. A 1-point reduction in hyperemia score is considered clinically meaningful.</description>
          <population>Per protocol (PP)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored for each patient until Day 84 (exit).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vehicle Eye Drops</title>
          <description>One drop, three times daily to the study eye for 28 days&#xD;
Vehicle Eye Drops: One drop, three times daily to the study eye for 28 days</description>
        </group>
        <group group_id="E2">
          <title>0.1% AG-86893 Eye Drops</title>
          <description>One drop, three times daily to the study eye for 28 days&#xD;
0.1% AG-86893 Eye Drops: One drop, three times daily to the study eye for 28 days</description>
        </group>
        <group group_id="E3">
          <title>0.3% AG-86893 Eye Drops</title>
          <description>One drop, three times daily to the study eye for 28 days&#xD;
0.3% AG-86893 Eye Drops: One drop, three times daily to the study eye for 28 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (21.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival Discoloration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Eye pruritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Episcleritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tan Nguyen</name_or_title>
      <organization>Allgenesis Biotherapeutics</organization>
      <phone>+886-2-8787-1232</phone>
      <email>tan.nguyen@allgenesis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

